Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year

IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

See all formats and pricing
More options …
Volume 46, Issue 4 (Apr 2008)


Serum levels of the osteoprotegerin, receptor activator of nuclear factor κ-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction

Antonios Halapas
  • 1Department of Experimental Physiology, Medical School, University of Athens, Athens, Greece and Department of Cardiology, General Hospital G. Genimmatas, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Achilleas Zacharoulis / Stamatios Theocharis
  • 3Department of Forensic Medicine and Toxicology, Medical School, University of Athens, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Apostolos Karavidas / Dimitrios Korres / Kostantinos Papadopoulos / Harris Katopodis / Anastasia Stavropoulou / Peter Lembessis / Costas Xiromeritis / Apostolos Zacharoulis / Michael Koutsilieris
Published Online: 2008-02-26 | DOI: https://doi.org/10.1515/CCLM.2008.091


Background: Osteoprotegerin (OPG) and receptor activator of nuclear factor κ-B ligand (RANKL) are critical regulators of bone remodeling and RANKL/RANK signaling could also play an important role in the remodeling process of several tissues, such as myocardium. Therefore, we investigated whether the serum concentrations of OPG and RANKL correlate with the serum levels of metalloproteinase-1 (MMP-1), MMP-9 and tissue inhibitors of MMP-1 (TIMP-1), which are known regulators of myocardial healing in acute myocardial infarction (AMI) patients.

Methods: We analyzed blood samples from 51 consecutively hospitalized men with AMI, 12 men with established ischemic heart failure (New York Heart Association category II, NYHA-II) and 12 healthy men age-matched to the NYHA-II patients. Serum levels of MMP-1, MMP-9, TIMP-1, OPG and RANKL were quantified using commercially available ELISA kits. AMI patients were sampled 4 days and 6 months after MI.

Results: Our data revealed increased serum levels of OPG, RANKL, MMP-1 and TIMP-1 levels and significant correlations between increased RANKL levels and MMP-1 and TIMP-1 serum levels 6 months after MI. In addition, the ratio OPG/RANKL was very low 6 months after MI, suggesting that the nuclear factor κ-B signaling is possibly more active 6 months post-MI than it is on day 4 post-MI.

Conclusions: Our data suggest that OPG, RANKL, MMP-1 and TIMP-1 serum levels can be potential mediators of myocardial healing after MI. However, further large studies are needed to confirm the utility of OPG and RANKL as markers of healing after ST elevation in MI.

Clin Chem Lab Med 2008;46:510–6.

Keywords: extracellular matrix; matrix metalloproteinases; myocardial infarction; osteoprotegerin; receptor activator of nuclear factor κ-B ligand; tissue inhibitors of metalloproteinase

About the article

Corresponding author: Michael Koutsilieris, MD, PhD, Professor and Director, Department of Experimental Physiology, Medical School, University of Athens, 75 Micras Asias Goudi, Athens, 115 27 Greece Phone: +30-210-7462597, Fax: +30-210-7462571,

Received: 2007-09-25

Accepted: 2007-12-08

Published Online: 2008-02-26

Published in Print: 2008-04-01

Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 14374331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2008.091.

Export Citation

©2008 by Walter de Gruyter Berlin New York. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Dorette Raaz-Schrauder, Michael G. Schrauder, Christian Stumpf, Piotr Lewczuk, Tobias Kilian, Barbara Dietel, Christoph D. Garlichs, Christian Schlundt, Stephan Achenbach, and Lutz Klinghammer
Heart and Vessels, 2017
Nguyen T. Nguyen, Xiaolin Zhang, Cathy Wu, Richard A. Lange, Robert J. Chilton, Merry L. Lindsey, Yu-Fang Jin, and Christos A. Ouzounis
PLoS Computational Biology, 2014, Volume 10, Number 3, Page e1003472
Li-Pang Chuang, Ning-Hung Chen, Shih-Wei Lin, Ying-Ling Chang, I-Ju Chao, and Jong-Hwei S. Pang
Life Sciences, 2013, Volume 93, Number 5-6, Page 220
Thor Ueland, Arne Yndestad, Christen P. Dahl, Lars Gullestad, and Pål Aukrust
Current Heart Failure Reports, 2012, Volume 9, Number 2, Page 92
Lucia Gatta, Andrea Armani, Ferdinando Iellamo, Claudia Consoli, Francesca Molinari, Giuseppe Caminiti, Maurizio Volterrani, and Giuseppe M.C. Rosano
International Journal of Cardiology, 2012, Volume 155, Number 3, Page 409
Hailong Cao, Qingguo Li, Mingna Li, Røe OD, Zhong Wu, Qing Zhou, Bin Cao, Baojun Chen, Yijiang Chen, and Dongjin Wang
International Journal of Cardiology, 2013, Volume 166, Number 3, Page 702
Chung-Pin Liu, Jwu-Lai Yeh, Bin-Nan Wu, Chee-Yin Chai, Ing-Jun Chen, and Wen-Ter Lai
British Journal of Pharmacology, 2011, Volume 162, Number 1, Page 126
Anastassios Philippou, Gregory Bogdanis, Maria Maridaki, Antonis Halapas, Antigone Sourla, and Michael Koutsilieris
Clinical Chemistry and Laboratory Medicine, 2009, Volume 47, Number 6

Comments (0)

Please log in or register to comment.
Log in